Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Subject Matter was a Washington, D.C.-based public affairs, strategic communications, government relations, and advertising firm formed in 2015 through the merger of Elmendorf | Ryan and Home Front Communications. The firm served clients across sectors including public health, finance, education, technology, transportation, and communications, and described its offering as "creative advocacy." In 2023, Subject Matter merged with Kivvit to form Subject Matter+Kivvit, and in January 2024 the combined organization rebranded as Avoq. It was not a biotech, pharma, or healthcare operating company, although it supported some healthcare and public health clients through communications and advocacy services.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Subject Matter Public Affairs.